Appropriations Report Reminds FDA To Notify Congress Of Drug Safety Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress' omnibus spending bill conference report chastises FDA for failing to promptly provide documents to House and Senate Appropriations Committees
You may also be interested in...
Sen. Grassley Plans Legislation On Independence Of FDA Drug Safety Office
Finance Committee chair acknowledges he does not have enough votes for such legislation but says he is starting the "process of educating my colleagues" and "intends to continue that until we get this job done." Grassley's requested GAO report on the Office of Drug Safety will take several months.
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.